| Dossier: | Ctd |
|---|---|
| Transport Package: | Free |
| Specification: | 7mg/ml |
| Trademark: | Sinolead |
| Origin: | China |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Generic Name | Compound Betamethasone Injection |
| Strength | 7mg/ml |
| Packing | 5amps/box |
| Origin | China |
This product is white suspension.
This product is suitable for the treatment of acute and chronic diseases sensitive to glucocorticoids. Glucocorticoid therapy is an adjunct therapy to conventional therapy and cannot replace conventional therapy.
Musculoskeletal and soft tissue diseases: rheumatoid arthritis, osteoarthritis, bursitis, ankylosing spondylitis, epicondylitis, radiculitis, coccygeal pain, sciatica, low back pain, torticular neck, ganglion cyst, exostosis, fasciitis.
Allergic diseases: chronic bronchial asthma (including adjuvant treatment of asthma status), hay fever, angioneurotic edema, allergic bronchitis, seasonal or perennial allergic rhinitis, drug reactions, serum diseases, insect bites.
Skin diseases: atopic dermatitis (nummative eczema), neurodermatitis (localized simple moss), contact dermatitis, severe solar dermatitis, urticaria, hypertrophic lichen planus, diabetic lipoid progressive necrosis, alopecia areata, discoid lupus erythematosus, psoriasis, keloid, pemphigus, herpetiform dermatitis, cystic acne.
Collagen diseases: disseminated lupus erythematosus, scleroderma, dermatomyositis, nodular perivasculitis.
Oncology: Palliative care for adult leukemia and lymphoma, pediatric acute leukemia.
Other diseases: adrenal gonadal syndrome, ulcerative colitis, crohn's disease, inflammatory diarrhea, foot diseases (sclerophthalmia, bunion, varus of little toe), diseases requiring subconjunctival injection, glucocorticoid response, nephritis and nephrotic syndrome.
This product can treat primary or secondary adrenal insufficiency, but salt corticosteroids should be properly supplemented.
This product is recommended for:
(1) intramuscular injection treatment of diseases that respond to systemic glucocorticoid drugs;
(2) Direct injection into the soft tissue of patients with indications;
(3) Intra-articular and periarticular injections for the treatment of arthritis;
(4) Intracutaneous injection treatment of various skin diseases;
(5) Local injection for the treatment of certain foot inflammatory and cystic diseases.
Usage and dosage:
The doses required vary and must be individualized according to the nature of the disease, severity, and patient response.
The initial dose should be maintained or adjusted until satisfactory efficacy is achieved. If satisfactory clinical efficacy is not achieved after appropriate time of treatment, this product should be discontinued and other appropriate treatment methods should be used.
Systemic administration: For most diseases, the starting dose of systemic therapy is 1 to 2ml and can be repeated if necessary. The method of administration is deep intramuscular injection (IM) of the buttocks, and the dose and frequency of administration depend on the severity and efficacy of the condition. For patients with lupus erythematosus whose severe disease has been alleviated by appropriate rescue measures, the initial dose may be 2ml.
A variety of skin diseases by intramuscular injection of 1ml of this product after treatment. Repeated administration can be selected according to the condition.
In the treatment of respiratory diseases, symptoms can be relieved within hours after intramuscular injection of this product. For bronchial asthma, hay fever, allergic bronchitis and allergic rhinitis, injection of 1 to 2ml of this product can effectively control symptoms.
In the treatment of acute or chronic synovial bursitis, intramuscular injection of 1 to 2ml of this product has excellent efficacy, and can be repeated if necessary.
Matters needing attention:
This product contains benzyl alcohol and is prohibited for intramuscular injection in children.
This product should not be given intravenously or subcutaneously.
The aseptic operation regulations must be strictly followed when using this product.
This product contains two betamethasone esters, one of which is betamethasone sodium phosphate, which quickly disperses at the injection site. Therefore, when using this product, the physician should take into account that the soluble ingredients contained in it may cause systemic effects.
Caution should be exercised when intramuscular injection of this product to patients with idiopathic thrombocytopenic purpura.
When intramuscular glucocorticoids are injected, they should be injected deep into large muscles to avoid local tissue atrophy.
Injection of corticosteroids into soft tissues, lesions and joints can cause local and systemic effects.
To rule out suppurative infection, the joint fluid should be examined. Avoid injecting drugs into previously infected joints. Joint pain and local edema are significantly increased, joint movement is further limited, and fever and discomfort suggest suppurative arthritis. If diagnosed, appropriate antimicrobial therapy should be given.
Glucocorticoids should not be injected into unstable joints, infected sites or paraphernalia. Repeated intra-articular injection in osteoarthritis can increase joint damage, and direct injection of glucocorticoids into the tendon can cause delayed tendon rupture, so it should be avoided.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}